About
Research
Email: amanda.harvey@stmarys.ac.uk
Biography
Reporting to the Provost, Amanda is Dean of Education and Outcomes, with responsibility for the Directorate of Educational Excellence and Student Outcomes, which consists of Academic Professional Development, Academic Partnerships, Apprenticeships, Academic Student Experience and Enhancement and Inclusion, Access & Widening Participation.
Amanda joined St Mary’s in 2024, having previously worked at Brunel University where she was Associate Pro-Vice Chancellor (Quality Assurance), previously holding roles as Deputy Dean (Academic Affairs) and Head of Biosciences. Prior to Brunel, Amanda worked at Royal Holloway, University of London and the University of Sheffield. She is also a Principal Fellow of Advance HE.
Research
Research profile
Amanda has taught across several different programmes including UG Biomedical and Life Sciences (Levels 4-6) and PG Molecular Medicine & Cancer Research, as well as supervising over 15 PhD researchers.
She has a 20-year track record of research in cancer cell biology focussing on breast cancer cell signalling and its significance in the advancement of knowledge about disease development, therapeutic intervention and drug resistance. In collaboration with RHUL Amanda developed a novel bioassay for identifying the therapeutic potential of plants with no previously known medical pedigree.
Qualifications and accreditations
- BSc Biochemistry University of Wales College of Cardiff
- PhD Institute for Cancer Studies, Faculty of Medicine, University of Sheffield
- PGCert (LTHE) Brunel University
Membership of professional bodies
- Principal Fellow Advance HE
- Fellow of Royal Society of Biology
- British Association for Cancer Research
- European Association for Cancer Research
- Member of the Biochemical Society
- Fellow of Royal Society of Biology
Publications
- Tree D, Harvey A, Rand-Weaver M. Integrated Programme Assessment: 10 years on (2025) Open Scholarship of Teaching and Learning, 4(1). Doi,10.56230/osotl.128.
- Harvey A and Tree D (2025). From Silos to Synthesis: Ensuring Interdisciplinary Education Through Synoptic Assessment. The Biochemist
- Jerin S, Harvey AJ, Lewis A. (2023) Therapeutic potential of protein tyrosine kinase 6 in colorectal cancer. Cancers (Special Edition. Kinase Signaling in Cancer). Cancers 15(4)3703.
- Box C, Pennington C, Hare S, Porter S, Edwards, Eccles S, Crompton M, Harvey AJ. (2023). Brk and Involucrin expression may predict breast cancer cell responses to vitamin D3. International Journal of Molecular Science (Special Edition. Targeting Breast Cancer: Strategies and Hopes) 24, 10757.
- Houghton-Gisby, J Kerslake R, Karteris E, Kefah Mokbel, K, Harvey AJ. (2022). ACBD3 Bioinformatic Analysis and Protein Expression in Breast Cancer Cells. International Journal of Molecular Science 23(16), 8881.
- Burmi R, Box G, Wazir U, Hussain H, Davies J, William C, Eccles S, Jiang W, Mokbel K, and Harvey AJ. (2022) Breast Tumour Kinase (Brk/PTK6) Contributes to Breast Tumour Xenograft Growth and Modulates Chemotherapeutic Responses In Vitro. Genes 13 (3), 402 – 402.
- Bömer M, Pérez-Salamó I, Florance HV, Salmon D, Dudenhoffer JH, Finch P, Cinar A, Smirnoff N, Harvey A*, Devoto A*. (2021). Jasmonates induce Arabidopsis bioactivities selectively inhibiting the growth of breast cancer cells through CDC6 and mTOR. New Phytologist 229, 2120-2134. Doi,10.1111/nph.17031. *joint corresponding author
- Harvey A, La Rooy A, Kent S, Rand-Weaver M, & Tree D (2021). A tale of two CATES – improving assessment through collaboration. In ‘The CATE Collection: Together in Collaborative Educational Leadership’ pp48-61. Advance HE (ISBN 978-1-9163593-6-9).
- Harvey A. and Houghton-Gisby J. (2020) ACBD3, Its Cellular Interactors, and Its Role in Breast Cancer. Cancer Studies and Therapeutics 5 (2). 1-7.ISSN 2002-7184.
- Chudasama D, Bo V, Hall M, Anikin V, Jeyaneethi J, Gregory J, Pados G, Tucker A, Harvey A, Pink R, Karteris E. (2017). Identification of novel cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers. Carcinogenesis 39(3), 407-417. Doi, 10.1093/carcin/bgx122.
Visit Amanda's Google Scholar profile.